Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612675 | 0.93 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL4611675 | 0.93 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL4612304 | 0.90 | CNR1 (0.56) | CNR2CNR1 | |
| SCHEMBL4245523 | 0.90 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL4251610 | 0.89 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL4611457 | 0.87 | CNR1 (0.54) | CNR2CNR1 | |
| SCHEMBL4613649 | 0.85 | CNR1 (0.74) | CNR2CNR1 | |
| SCHEMBL4611288 | 0.84 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL4612302 | 0.84 | CNR1 (0.74) | CNR2CNR1 | |
| SCHEMBL4612819 | 0.84 | CNR2 (0.47) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | claimed |
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | CNR2 209/4885CNR1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.